Enanta stockholders re-elect directors, approve equity plan amendment and say-on-pay

ENANTA PHARMACEUTICALS INC

Re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 14.3M and 16.7M votes for.
Approved amendment to 2019 Equity Incentive Plan to increase authorized shares by 975,000.
Advisory say-on-pay vote approved with 16.2M votes for versus 1.4M against.
Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2023-03-02 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-03-02

Exact text from the filing

The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ENANTA PHARMACEUTICALS INC shareholders approved Election of Two Class I Directors at the 2023-03-02 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-03-02

Exact text from the filing

The stockholders re-elected the following individuals as Class I directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Bruce L.A. Carter, Ph.D. 14,297,051 3,316,218 1,371,281 Jay R. Luly, Ph.D. 16,673,120 940,149 1,371,281

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved by 975,000 shares at the 2023-03-02 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-03-02

Exact text from the filing

The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ENANTA PHARMACEUTICALS INC shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023 at the 2023-03-02 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-03-02

Exact text from the filing

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-006453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.